Mar 9, 2026 10:56AM Cantor Fitzgerald Upgrades Cartesian Therapeutics (RNAC) to Overweight

Jan 9, 2026 08:05AM Cartesian advances Descartes-08 trials across multiple autoimmune conditions

Nov 19, 2025 06:40AM Cartesian Therapeutics (RNAC) PT Lowered to $30 at H.C. Wainwright

Nov 14, 2025 06:45AM Cartesian Therapeutics (RNAC) PT Raised to $44 at BTIG

Nov 6, 2025 08:11AM Cartesian Therapeutics (RNAC) Misses Q3 EPS by 138c

Oct 21, 2025 07:04AM Cartesian Therapeutics eliminates chief scientific officer position

Oct 8, 2025 07:04AM Cartesian Therapeutics appoints June Seymour as chief accounting officer

Aug 7, 2025 08:07AM Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c

Jul 9, 2025 06:36AM Wedbush Starts Cartesian Therapeutics (RNAC) at Outperform

Jun 2, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

May 30, 2025 12:12PM BTIG Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

May 30, 2025 07:01AM Cartesian Therapeutics (RNAC) Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025 04:29PM Cartesian Therapeutics (RNAC) Misses Q1 EPS by 68c

Apr 8, 2025 07:01AM Cartesian Therapeutics' (RNAC) Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Mar 17, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on Cartesian Therapeutics (RNAC)

Mar 17, 2025 06:39AM Cartesian Therapeutics (RNAC) PT Lowered to $40 at H.C. Wainwright

Jan 28, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

Dec 19, 2024 05:55AM BTIG Starts Cartesian Therapeutics (RNAC) at Buy

Dec 13, 2024 04:20PM Cartesian Therapeutics (RNAC) Files for 11.39M Share Offering by Selling Stockholders

Dec 13, 2024 04:18PM Cartesian Therapeutics (RNAC) Files for 6.25M Share Offering by Selling Stockholders

Dec 4, 2024 06:48AM Cartesian Therapeutics (RNAC) PT Raised to $45 at H.C. Wainwright

Dec 3, 2024 06:01AM Cartesian Therapeutics (RNAC) Reports Positive Updated Results from Phase 2b Trial of Descartes-08

Oct 15, 2024 07:03AM Cartesian Therapeutics (RNAC) Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Sep 25, 2024 02:34PM Mizuho Reiterates Outperform Rating on Cartesian Therapeutics (RNAC)

Sep 20, 2024 04:20PM Cartesian Therapeutics (RNAC) Files for 6.5M Share Offering by Selling Stockholders

Sep 13, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

Sep 9, 2024 04:15PM Cartesian Therapeutics (RNAC) Files for 6.5M Share Offering by Selling Stockholders

Sep 9, 2024 07:03AM Cartesian Therapeutics (RNAC) Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Sep 4, 2024 07:30AM H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

Sep 3, 2024 07:05AM Cartesian Therapeutics (RNAC) Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Aug 9, 2024 07:33AM Cartesian Therapeutics (RNAC) PT Lowered to $41 at Needham

Aug 8, 2024 07:23AM Cartesian Therapeutics, Inc. (RNAC) Tops Q2 EPS by 144c

Aug 6, 2024 05:31AM TD Cowen Starts Cartesian Therapeutics (RNAC) at Buy

Jul 3, 2024 06:40AM Cartesian Therapeutics (RNAC) PT Lowered to $49 at H.C. Wainwright

Jul 3, 2024 06:33AM Mizuho Reiterates Outperform Rating on Cartesian Therapeutics (RNAC)

Jul 2, 2024 04:07PM Cartesian Therapeutics (RNAC) Appoints Kemal Malik to its Board

Jul 2, 2024 11:27AM Oppenheimer Downgrades Cartesian Therapeutics (RNAC) to Perform

Jul 2, 2024 06:32AM Cartesian Therapeutics (RNAC) Doses First Patient in Phase 2 Trial of Descartes-08

Jul 2, 2024 06:32AM Cartesian Therapeutics (RNAC) Enters $130M Private Placement

Jul 2, 2024 06:30AM Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08